Dr. Paul Baas of the Netherlands Cancer Institute and the University of Leiden in Amsterdam recently presented on the CheckMate 743 study at the International Association for the Study of Lung Cancer World Conference. The randomized phase III Checkmate 743 clinical trial prescribed mesothelioma patients who were not candidates for surgery with a combination of first-line nivolumab and ipilimumab. The promising results yielded a four-month improvement in median overall survival for patients who received the new dual-immunotherapy regimen as compared with those who had received platinum-based chemotherapy, the current double-chemotherapy standard of care for mesothelioma. “This is the first positive […]
The post New Dual-Immunotherapy Regimen Proves Effective for Mesothelioma Patients in Phase 3 Clinical Trial appeared first on Mesothelioma Help Cancer Organization.
from Blog – Mesothelioma Help Cancer Organization https://ift.tt/3482DZb
via IFTTT
No comments: